XOMA Royalty Corp.
NASDAQ:XOMABiotechnology
+$0.19 today
- Market cap
- $503.77M
- Beta
- 0.87
- P/E (TTM)
- 15.8
- EPS (TTM)
- $2.65
Volume 4.22M
Average 0.21M
XOMA Capital Expenditures
Cash spent on property, plant, equipment, and other long-term assets.
XOMA Royalty Corp.NASDAQ: XOMA
Capital Expenditures · Q1 FY2026 · quarter ended Mar 2026
Capital expenditures outflow grows to $0
Q1 FY2026 capital expenditures was $0, compared with $0 a year earlier. Trailing-twelve-month capital expenditures was $0.
Context
- Capital expenditures amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
- Capital expenditures increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly capital expenditures holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.
Sources:Cash FlowText generated from reported figures; not investment advice.
Capital Expenditures history
USD · from the cash flow
- Latest · FY2025
- 0 USD
- Year-over-year change
- +100.0%
| Period | Period end | Capital Expenditures | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | +100.0% |
| FY2024 | 2024-12-31 | (20K) | -17.6% |
| FY2023 | 2023-12-31 | (17K) | +99.9% |
| FY2022 | 2022-12-31 | (15.25M) | +42.5% |
| FY2021 | 2021-12-31 | (26.5M) | — |
Capital Expenditures vs competitors
How XOMA compares with its peers on the latest reported figures
- XOMA's LTM Mar 2026 capital expenditures of $0 is the 9th largest of the 10 companies compared; the peer median is $169K.
- Its year-over-year change of +100.0% is the highest of 9, against a peer median of -50.7%.
- Capital expenditures amounts to 0.0% of revenue for XOMA, versus a peer median of 50.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $18.2M | -57.2% | +35.8% | 19.7% | |
| LTM Mar 2026 | $1.49M | -69.3% | -38.3% | 80.4% | |
| LTM Mar 2026 | $1.19M | +88.9% | -27.4% | — | |
| LTM Mar 2026 | $362K | -73.2% | -25.8% | — | |
| LTM Mar 2026 | $169K | -96.0% | -62.9% | — | |
| LTM Mar 2026 | $121K | -44.2% | -40.5% | — | |
| LTM Mar 2026 | $36.19K | +29.2% | -21.0% | — | |
| LTM Mar 2026 | $27.51K | +48.2% | +11.5% | — | |
| LTM Mar 2026 | $0 | +100.0% | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | — | |
| Peer median (excluding XOMA) | $169K | -50.7% | -26.6% | 50.0% | |
Competitors are the stored peer set for XOMA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 15.8M | (17.1M) | (40.83M) | (13.82M) | 31.71M |
| Depreciation & Amortization | 7K | 104K | 900K | 216K | 2.97M |
| Deferred Income Tax | 0 | 0 | 0 | (5.66M) | 103K |
| Stock-Based Compensation | 6.2M | 3.61M | 9.1M | 10.31M | 9.27M |
| Change in Working Capital | (886K) | (181K) | (3.53M) | (2.79M) | (11.37M) |
| Accounts Receivables | 1.58M | 208K | (1M) | (835K) | (2.43M) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 765K | 1.85M | (523K) | 1.6M | (10.6M) |
| Other Working Capital | (3.23M) | (2.23M) | (2M) | (3.55M) | 1.65M |
| Other Non-Cash Items | 1.56M | 694K | 16.2M | (2.01M) | (29.82M) |
| Operating Cash Flow | 22.68M | (12.88M) | (18.16M) | (13.75M) | 2.87M |
| Capital Expenditures | (26.5M) | (15.25M) | (17K) | (20K) | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | (1.25M) | 3.85M |
| Purchases of Investments | 0 | 0 | 0 | (3.24M) | (99K) |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | (26.5M) | (4.97M) | (694K) | (23.75M) | 47.14M |
| Investing Cash Flow | (26.5M) | (20.22M) | (711K) | (28.26M) | 50.89M |
| Debt Repayment | (4.25M) | 0 | 130M | (6.9M) | (10.6M) |
| Common Stock Issued | 1.58M | 2.42M | 466K | 5.21M | 8.72M |
| Common Stock Repurchased | 0 | 0 | (148K) | (13K) | (16.04M) |
| Dividends Paid | (3.5M) | (5.47M) | (5.47M) | (5.47M) | (5.47M) |
| Other Financing Activities | (21M) | (1.4M) | (3.79M) | 1.26M | (3.07M) |
| Financing Cash Flow | 12.84M | (4.45M) | 120.59M | (11.13M) | (26.46M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 9.01M | (37.55M) | 101.72M | (53.13M) | 27.29M |
| Free Cash Flow | (3.82M) | (28.13M) | (18.18M) | (13.77M) | 2.87M |
XOMA Royalty Corp.
NASDAQ:XOMA
Intrinsic Alpha fair value
Locked
Current Price
$40.17
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.